Skip to main content
. 2019 May 15;9(27):15196–15204. doi: 10.1039/c9ra00330d

Fig. 6. (a) Cell viabilities of Lipofectamine™ 2000 and CSO–SA on HepG2.2.15 cells and L02 cells. (b) Cell viabilities of Lipofectamine™ 2000/DrzBS and CSO–SA/DrzBS on HepG2.2.15 cells and L02 cells with different DrzBS concentration. Error bars represent the standard deviation (mean ± SD, n = 3).

Fig. 6